Dear member of the investment community,

Actelion Ltd will host a Conference Call / Audiocast on following the US FDA approval of Opsumit® (macitentan) for the treatment of pulmonary arterial hypertension today, on Monday, 21 October 2013, at 14.00 CET / 13.00 BST / 08.00 a.m. EST.

The company announced on the 18 October 2013 that the United States Food and Drug Administration (FDA) has approved the use of the orally available endothelin receptor antagonist Opsumit® (macitentan) 10 mg once daily for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression.

Date/Time:

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.

Participant`s mode:

Listen-Only with possibility to open individual lines during Q&A session. Participants will be asked for their Name and Company.

Audiocast Access:

Audiocast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.

Participant`s mode:

Listen only

Audiocast Replay:

The archived Investor Audiocast will be available for replay through http://www.actelion.com approximately 60 minutes after the call has ended.

For further information please contact:

Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
+41 61 565 62 62
+1 646 737 49 72
http://www.actelion.com

Invitation PDF

---

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
HUG#1736798